Skip to content
Home/Companies/Biotech/Congruence Therapeutics
Congruence Therapeutics

Congruence Therapeutics

Biotech·Canada·Active·5yr hold
Entry
2021
Hold
5yr
Status
Active

Who owns Congruence Therapeutics?

Congruence Therapeutics is currently owned by Angelini Ventures through Angelini Ventures (2022 vintage), since 2021.

Hand-verified · updated 2026-07-26

Angelini Ventures
Investor
Angelini Ventures
Angelini Ventures · 2022 · Life Sciences VC

Key facts

HQCanada
SectorBiotech
StatusActive
Websitecongruencetx.com

More from Angelini Ventures

Other portfolio companies in the same fund.

Handspring Health
Active
HealthTechUS· 2026
Hypervision Surgical
Active
MedTechUK· 2026
Adcytherix
Active
BiotechFrance· 2025
Elkedonia
Elkedonia
Active
BiotechFrance· 2025
Laigo Bio
Laigo Bio
Active
BiotechNetherlands· 2025
Nobi
Active
MedTechBelgium· 2025

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Congruence Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Congruence Therapeutics?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Congruence Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue